Reveragen Biopharma, Inc.

ROCKVILLE, MD 20850

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $4.3MM
First Award Date 09/16/10
Most Recent Award Date 02/01/17

Key Personnel

Last Name Name Awards Contact
Reeves Erica Reeves 1
DAMSKER JESSE DAMSKER 4
CLEMENS PAULA R CLEMENS 2
HOFFMAN ERIC P HOFFMAN 2

7 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-265
Budget: 02/01/17 - 01/31/18

? DESCRIPTION (provided by applicant): ReveraGen BioPharma is a clinical stage drug development company that is developing VBP15, a novel dissociative steroidal class drug. The initial indication for development is Duchenne muscular dystrophy, where VBP15 holds promise for retaining or increasing efficacy of glucocorticoids, while reducing si...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-15-270
Budget: 04/01/16 - 03/31/17

? DESCRIPTION (provided by applicant): Glucocorticoids (GC's), such as prednisolone, are used frequently to induce remission and treat multiple sclerosis (MS). Despite effectiveness, many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of MS patients. These side effects are beli...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PAR-14-265
Budget: 02/15/16 - 01/31/17

? DESCRIPTION (provided by applicant): ReveraGen BioPharma is a clinical stage drug development company that is developing VBP15, a novel dissociative steroidal class drug. The initial indication for development is Duchenne muscular dystrophy, where VBP15 holds promise for retaining or increasing efficacy of glucocorticoids, while reducing si...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/01/15 - 08/31/16

DESCRIPTION (provided by applicant): Glucocorticoids (GC's), such as prednisolone, are used frequently to induce remission and treat rheumatoid arthritis (RA). Despite effectiveness, many GC-mediated detrimental side effects including osteoporosis and muscle atrophy limit long-term chronic treatment of RA patients. In addition, juvenile arthriti...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-14-072
Budget: 09/22/14 - 08/31/15

DESCRIPTION (provided by applicant): Glucocorticoids (e.g. prednisolone) are prescribed frequently to treat inflammatory bowel disease (IBD). Despite effectiveness, adverse side effects believed to be caused by GRE-mediated transcriptional properties limit long term use of glucocorticoids in IBD patients. Furthermore, these GRE-mediated transcri...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: RFA-MD-13-009
Budget: 07/23/14 - 06/30/15

DESCRIPTION (provided by applicant): The treatment of pain in Sickle Cell Disease (SCD) is challenging for both patients and providers and is associated with significant disparities in healt care delivery. While the role of ongoing inflammation during vasooclusive crisis and pain is recognized, effective therapeutic interventions are lacking. Gl...

Phase 1 STTR

Agency: Department of Health & Human Services
Topic: PA-09-081
Budget: 09/16/10 - 08/31/12

DESCRIPTION (provided by applicant): Asthma is a very common lung condition in children, and incidence is increasing in the US particularly in urban and minority populations. The standard of care for asthmatics is inhaled steroid, although clinical response is variable. The mechanism of efficacy of steroids in asthma is thought to be via anti-in...